Literature DB >> 28115964

Hereditary angioedema: health-related quality of life in Canadian patients as measured by the SF-36.

Nina Lakhani Jindal1, Elaine Harniman2, Nieves Prior3, Elia Perez-Fernandez4, Teresa Caballero5,6, Stephen Betschel1.   

Abstract

BACKGROUND: Hereditary angioedema (HAE) is a rare but serious condition characterized by recurrent spontaneous attacks of angioedema affecting superficial tissues of upper respiratory and gastrointestinal tracts. The potentially fatal and disfiguring nature of HAE impacts the health-related quality of life (HRQoL) of patients with this condition.
OBJECTIVES: To assess the health-related quality of life of Canadian patients with HAE using the 36-item Short-Form Health Survey (SF-36v2).
METHODS: Twenty-one patients living in Canada over age 18 with known diagnosis of hereditary angioedema due to C1-INH deficiency (HAE), completed the SF-36v2 (generic HRQoL questionnaire). Results were compared to Canadian normative data by converting the SF-36 scores into z scores.
RESULTS: The SF-36v2 showed a significant reduction in general health (p = 0.0063) in patients with HAE when compared with healthy Canadians. Percentage of patients with z scores below 0.8 (large effect) was 47.6% for general health subscale, 33.3% for bodily pain and vitality subscales and 28.6% for physical component scores. Mean scores of eight dimensions ranged from 57.7 to 88.9. Mean Physical and mental component scores were 49.1 and 50.4. Internal consistency of evaluation was demonstrated by Cronbach's alpha value above 0.7 for all scales. General perception of health was significantly different in these patients, compared to Canadian normative data.
CONCLUSIONS: This study of Canadian patients with HAE shows that General Health is most frequently affected followed by Bodily Pain and Vitality, as measured by SF-36v2. The SF-36v2 offers valuable insight to assess quality of life in patients with HAE, however a larger number of Canadian patients and specific tools for assessment are needed for better evaluation.

Entities:  

Keywords:  C1-inhibitor; HAE; Hereditary angioedema; Quality of Life; SF-36

Year:  2017        PMID: 28115964      PMCID: PMC5244704          DOI: 10.1186/s13223-016-0176-3

Source DB:  PubMed          Journal:  Allergy Asthma Clin Immunol        ISSN: 1710-1484            Impact factor:   3.406


Background

Hereditary angioedema (HAE) is a rare but serious condition due to a deficiency in serine protease inhibitor C1 inhibitor (C1INH), leading to accumulation of bradykinin [1]. It is characterized by recurrent attacks of swelling affecting any part of the body, most commonly involving the extremities, face, genitals, gastrointestinal tract and upper airways. HAE is an autosomal dominant condition caused by mutations in the SERPING1 gene, with 25% of cases representing a de novo mutation, without a family history of disease [1, 2]. The estimated prevalence of HAE is between 1:30,000 and 1:80,000, with no predilection for gender, race or ethnicity [1]. Episodes of swelling follow a stereotypic pattern in which worsening of bradykinin-mediated edema occurs over 24 h, peaks and slowly resolves over the subsequent 48–72 h [1, 3]. Certain trigger factors have been identified including emotional stress, local trauma, dental or medical procedures, infection, menstruation and the use of hormonal contraception [1, 2]. Despite this, severity of attacks remains unpredictable at onset and if affecting the upper airways, can lead to obstruction, asphyxiation and death [4]. Gastrointestinal attacks can cause significant pain and often are mistaken for acute abdomen, leading to unnecessary surgical intervention [5]. Edema affecting the skin and extremities causes disfigurement and if severe, compartment syndrome [1]. The unpredictable, potentially fatal as well as disfiguring nature of the disease impacts the health-related quality of life (HRQoL) of patients with this condition, however few publications have described the quality of life in patients with HAE. The Short Form 36 (SF-36v2) is a standardized patient reported survey of patient health, and is a measure of health status commonly used in health economics. The aim of this study was to assess the health-related quality of life of Canadian patients with hereditary angioedema using the 36-item Short-Form Health Survey (SF-36v2).

Methods

Ethical aspects

Study protocol was approved by the Research and Ethics Board of St. Michael’s Hospital, Toronto and the Faculty of Medicine at the University of Toronto. Patients were recruited through the Canadian HAE patient network and treating physicians across Canada. Informed consent was obtained from all patients before study questionnaires were completed.

Patient population

Twenty-one patients living in Canada over the age of 18 with a known laboratory confirmed diagnosis of hereditary angioedema due to C1-INH deficiency (HAE) were included in the study (Table 1).
Table 1

Descriptive analysis and Cronbach’s alpha values for the eight subscales and two summary scales of the SF-36 in 21 hereditary angioedema patients

DomainMinimumMaximumMedianMeanStandard deviationCronbach’s alphaFloor n (%)Ceiling n (%)
Physical functioning (PF)40.00100.0095.0087.8616.250.860 (0)8 (38.10)
Role physical (RP)0.00100.0093.7584.2323.190.911 (4.76)7 (33.33)
Bodily pain (BP)22.00100.0074.0067.9021.790.890 (0)3 (14.29)
General health (GH)5.00100.0062.0061.0523.390.840 (0)1 (4.76)
Vitality (VT)25.0081.2562.5057.7418.320.830 (0)0 (0)
Social functioning (SF)0.00100.00100.0085.1227.280.951 (4.76)13 (61.90)
Role emotional (RE)16.67100.00100.0088.8924.490.940 (0)16 (76.19)
Mental health (MH)25.0090.0080.0076.1916.950.890 (0)0 (0)
Physical summary (PCS)34.1763.2148.6249.13N/AN/AN/A
Mental summary (MCS)15.9965.8854.6050.35N/AN/AN/A
Descriptive analysis and Cronbach’s alpha values for the eight subscales and two summary scales of the SF-36 in 21 hereditary angioedema patients

Data collection

Patients completed the generic SF-36v2

SF-36v2 is a generic health questionnaire measuring eight health domains including physical functioning (PF), limitations in daily role functioning due to physical problems (RP), bodily pain (BP), general health (GH), vitality (VT), social functioning (SF), limitations in daily role functioning due to emotional problems (RE), mental health (MH) as well as an item asking respondents about health change over the past year. Scores for each domain can range from 0 to 100, higher scores indicating better health state. Scores on each scale were calculated based on the ‘half item rule’. Two summary scores were also calculated from the eight domains: the physical component summary (PCS) and the mental health component summary (MCS). Summary scores are normalized to age-matched controls and scored to have a mean of 50 and standard deviation of 10.

Statistical analysis

Descriptive statistics for demographic information were calculated. Results were compared to Canadian normative data by converting the SF-36v2 scores into z-scores. Z-scores with values above 0.80 are considered to have large effects. Each person’s score was standardized by subtracting the mean value and dividing by the standard deviation for the Canadian norms of the same age and gender group [6]. This z-score has a mean of 0 and a standard deviation of 1. This method of examining differences between samples is similar to calculating effect sizes [7]. Thus, the z-scores can be interpreted in the same way with values above 0.80 considered large effects. We used a one-sample t test, with zero as test value, to determine if significant differences (p < 0.05) from age- and gender-matched Canadian norms existed. Cronbach’s alpha was used to assess the internal consistency of each subscale and a value equal to or greater than 0.7 was considered acceptable. Data were analyzed using SAS software, version 9.4 (SAS Institute, Cary, NC).

Results

Twenty-one patients were included in the study. The majority of patients were female (20 = 95.2%), from an urban area (15 = 71.4%), and had an education level above high school (15 = 71.4%) and a medium–low socio-economic level (8 = 44.4%). The mean age was 42.3 years (SD 13.7 years). The percent of patients with a z score below 0.8 (large effect) was 47.6% for General Health subscale, 33.3% for Bodily Pain and Vitality subscales, and 28.6% for the physical component summary score. The SF-36v2 showed there was a significant reduction in general health (p = 0.0063) in patients with hereditary angioedema (HAE) when compared with healthy Canadians (Table 2). The mean scores of the eight dimensions ranged from 57.7 to 88.9. The mean Physical and Mental Component Summary Scores were 49.1 and 50.3. General perception of health was significantly different in this patient population, compared to Canadian normative data. There were no significant relationships between SF-36v2 scores and age or education level.
Table 2

SF36v2 HAE patients compared to Canadian normative data [6]

SF-36 domain≥0.8 SD below0.5–0.8 SD belowwithin 0.5 SD of mean0.5–0.8 SD above≥0.8 SD aboveMean (sd)p valuea
Physical functioning14.314.323.842.94.80.06 (0.73)0.6926
Role-physical4.84.861.928.60.00.08 (0.71)0.6197
Bodily pain33.39.542.90.014.3−0.29 (0.98)0.1991
General health47.64.833.34.89.5−0.95 (1.42)0.0063
Energy/vitality33.39.523.828.64.8−0.29 (1.05)0.2207
Social functioning14.34.819.142.919.10.02 (1.40)0.9607
Role-emotional14.30.09.576.20.00.20 (0.81)0.2669
Mental health14.34.833.319.128.60.02 (1.13)0.9303
Physical component scale28.614.333.39.514.3−0.23 (0.99)0.3027
Mental component scale19.10.033.333.314.3−0.05 (1.39)0.8825

aFrom one sample t test

SF36v2 HAE patients compared to Canadian normative data [6] aFrom one sample t test Cronbach’s alpha exceeded 0.70 for all scales, very high ceiling effects occurred for the SF-36 RE (76.2%) and SF subscales (61.9%) followed by the PF (38.1%) and RP (33.3%) subscales. Cronbach’s alpha for these four subscales ranged from 0.86 to 0.95 while the range for the other four subscales was 0.83–0.89. Two items (sf8 and sf3d) each had one missing value (4.8%).

Discussion

Hereditary angioedema is a rare but serious condition, in which affected patients suffer a significant burden of disease, similar to that of severe asthma or Crohn’s disease [8]. Additionally, patients with HAE deal with the uncertainties and unpredictable nature of episodic attacks of angioedema. Few studies have evaluated the quality of life in patients with HAE [3, 9]. In this study, Canadian patients exhibited an impaired quality of life, as measured by the standardized SF-36v2, particularly in the domains of general health, bodily pain and vitality. In previous data, patients with HAE reported decreased mental and physical health as well as social effects compared to a normal population, in keeping with our study of Canadian patients [3, 9, 10]. In both the study by Gomide [10] and our study, the SF-36 subscales with the lowest median values were General Health, Bodily Perception and Vitality (40, 52, and 60 respectively for the Gomide [10] study and 62.0, 74.0, and 62.5 respectively for our study). The median value for the SF subscale differed between the two studies (median value of 50 vs. 100). A more recent Danish study by Aabom et al. showed mean SF-36v2 scores corresponding with population norms, likely explained by differences in treatment options and access to around the clock counseling for Danish patients [11]. The high Cronbach’s alpha for all SF-36 scales indicates a high internal consistency. However, the high alpha coefficients observed might be partly due to the ceiling effects observed in some subscales (mainly RE and SF, but also PF and RP). These ceiling effects could be related to a low sensitivity of these subscales or to nearly no affection of these subscales in Canadian HAE patients. Health-related quality of life questionnaires are developed to evaluate individual patient health status, assess the cost-effectiveness of an intervention or treatment, and to monitor disease burden. Several questionnaires have been developed to evaluate health related quality of life and help establish resource allocation [12]. The standardized SF-36v2 questionnaire can be a useful tool in the assessment of quality of life in patients with HAE, which allows comparison to other diseases, however a need exists for disease-specific surveys, to serve as a more precise indicator of disease burden. Disease-specific surveys can serve as a point of comparison with generic questionnaires and further evaluate particular aspects of disease severity. A specific HAE QOL questionnaire has been developed in Spain and translated and validated in other countries [13, 14].

Conclusion

This study of Canadian patients with HAE shows that General Health is most frequently affected followed by Bodily Pain and Vitality, as measured by SF-36v2. The SF-36v2 offers valuable insight to assess quality of life in patients with HAE, however a larger number of Canadian patients and specific tools for assessment are needed for better evaluation.
  11 in total

1.  The humanistic burden of hereditary angioedema: Impact on health-related quality of life, productivity, and depression.

Authors:  William R Lumry; Anthony J Castaldo; Margaret K Vernon; Marc B Blaustein; David A Wilson; Patrick T Horn
Journal:  Allergy Asthma Proc       Date:  2010 Sep-Oct       Impact factor: 2.587

2.  The Aberdeen varicose vein questionnaire may be the preferred method of rationing patients for varicose vein surgery.

Authors:  Christopher R Lattimer; Evi Kalodiki; Mustapha Azzam; George Geroulakos
Journal:  Angiology       Date:  2013-01-31       Impact factor: 3.619

3.  Canadian normative data for the SF-36 health survey. Canadian Multicentre Osteoporosis Study Research Group.

Authors:  W M Hopman; T Towheed; T Anastassiades; A Tenenhouse; S Poliquin; C Berger; L Joseph; J P Brown; T M Murray; J D Adachi; D A Hanley; E Papadimitropoulos
Journal:  CMAJ       Date:  2000-08-08       Impact factor: 8.262

4.  2010 International consensus algorithm for the diagnosis, therapy and management of hereditary angioedema.

Authors:  Tom Bowen; Marco Cicardi; Henriette Farkas; Konrad Bork; Hilary J Longhurst; Bruce Zuraw; Emel Aygoeren-Pürsün; Timothy Craig; Karen Binkley; Jacques Hebert; Bruce Ritchie; Laurence Bouillet; Stephen Betschel; Della Cogar; John Dean; Ramachand Devaraj; Azza Hamed; Palinder Kamra; Paul K Keith; Gina Lacuesta; Eric Leith; Harriet Lyons; Sean Mace; Barbara Mako; Doris Neurath; Man-Chiu Poon; Georges-Etienne Rivard; Robert Schellenberg; Dereth Rowan; Anne Rowe; Donald Stark; Smeeksha Sur; Ellie Tsai; Richard Warrington; Susan Waserman; Rohan Ameratunga; Jonathan Bernstein; Janne Björkander; Kristylea Brosz; John Brosz; Anette Bygum; Teresa Caballero; Mike Frank; George Fust; George Harmat; Amin Kanani; Wolfhart Kreuz; Marcel Levi; Henry Li; Inmaculada Martinez-Saguer; Dumitru Moldovan; Istvan Nagy; Erik W Nielsen; Patrik Nordenfelt; Avner Reshef; Eva Rusicke; Sarah Smith-Foltz; Peter Späth; Lilian Varga; Zhi Yu Xiang
Journal:  Allergy Asthma Clin Immunol       Date:  2010-07-28       Impact factor: 3.406

5.  Self-administration of intravenous C1-inhibitor therapy for hereditary angioedema and associated quality of life benefits.

Authors:  Anette Bygum; Klaus Ejner Andersen; Carsten Sauer Mikkelsen
Journal:  Eur J Dermatol       Date:  2009 Mar-Apr       Impact factor: 3.328

6.  A focused parameter update: hereditary angioedema, acquired C1 inhibitor deficiency, and angiotensin-converting enzyme inhibitor-associated angioedema.

Authors:  Bruce L Zuraw; Jonathan A Bernstein; David M Lang; Timothy Craig; David Dreyfus; Fred Hsieh; David Khan; Javed Sheikh; David Weldon; David I Bernstein; Joann Blessing-Moore; Linda Cox; Richard A Nicklas; John Oppenheimer; Jay M Portnoy; Christopher R Randolph; Diane E Schuller; Sheldon L Spector; Stephen A Tilles; Dana Wallace
Journal:  J Allergy Clin Immunol       Date:  2013-06       Impact factor: 10.793

7.  Upper airway edema in 43 patients with hereditary angioedema.

Authors:  Ying-Yang Xu; Yu-Xiang Zhi; Rui-Ling Liu; Timothy Craig; Hong-Yu Zhang
Journal:  Ann Allergy Asthma Immunol       Date:  2014-04-01       Impact factor: 6.347

8.  Development of a disease-specific quality of life questionnaire for adult patients with hereditary angioedema due to C1 inhibitor deficiency (HAE-QoL): Spanish multi-centre research project.

Authors:  Nieves Prior; Eduardo Remor; Carmen Gómez-Traseira; Concepción López-Serrano; Rosario Cabañas; Javier Contreras; Ángel Campos; Victoria Cardona; Stefan Cimbollek; Teresa González-Quevedo; Mar Guilarte; Dolores Hernández Fernández de Rojas; Carmen Marcos; María Rubio; Miguel Ángel Tejedor-Alonso; Teresa Caballero
Journal:  Health Qual Life Outcomes       Date:  2012-07-20       Impact factor: 3.186

9.  Abdominal attacks and treatment in hereditary angioedema with C1-inhibitor deficiency.

Authors:  Eitan Rubinstein; Leslie E Stolz; Albert L Sheffer; Chris Stevens; Athos Bousvaros
Journal:  BMC Gastroenterol       Date:  2014-04-09       Impact factor: 3.067

10.  Hereditary angioedema: quality of life in Brazilian patients.

Authors:  Maria Abadia Consuelo M S Gomide; Eliana Toledo; Solange Oliveira Rodrigues Valle; Regis A Campos; Alfeu T França; Nieves Prior Gomez; Heitor Franco Andrade; Teresa Caballero; Anete S Grumach
Journal:  Clinics (Sao Paulo)       Date:  2013-01       Impact factor: 2.365

View more
  9 in total

1.  Hereditary angioedema from the patient's perspective: A follow-up patient survey.

Authors:  Aleena Banerji; Yu Li; Paula Busse; Marc A Riedl; Nicole S Holtzman; Huamin Henry Li; Mark Davis-Lorton; Jonathan A Bernstein; Michael Frank; Anthony J Castaldo; Janet Long; Bruce Zuraw; William Lumry; Sandra Christiansen
Journal:  Allergy Asthma Proc       Date:  2018-05-01       Impact factor: 2.587

2.  Impact of lanadelumab on health-related quality of life in patients with hereditary angioedema in the HELP study.

Authors:  William R Lumry; Karsten Weller; Markus Magerl; Aleena Banerji; Hilary J Longhurst; Marc A Riedl; Hannah B Lewis; Peng Lu; Giovanna Devercelli; Gagan Jain; Marcus Maurer
Journal:  Allergy       Date:  2020-12-24       Impact factor: 13.146

Review 3.  Disease Severity, Activity, Impact, and Control and How to Assess Them in Patients with Hereditary Angioedema.

Authors:  Anette Bygum; Paula Busse; Teresa Caballero; Marcus Maurer
Journal:  Front Med (Lausanne)       Date:  2017-12-04

4.  Treatment patterns and healthcare resource utilization among patients with hereditary angioedema in the United States.

Authors:  Marc A Riedl; Aleena Banerji; Michael E Manning; Earl Burrell; Namita Joshi; Dipen Patel; Thomas Machnig; Ming-Hui Tai; Douglas J Watson
Journal:  Orphanet J Rare Dis       Date:  2018-10-12       Impact factor: 4.123

5.  Health-related quality of life and its risk factors in Chinese hereditary angioedema patients.

Authors:  Shuang Liu; Xue Wang; Yingyang Xu; Qun Xu; Yuxiang Zhi
Journal:  Orphanet J Rare Dis       Date:  2019-08-08       Impact factor: 4.123

6.  Clinical characteristics and burden of illness in patients with hereditary angioedema: findings from a multinational patient survey.

Authors:  Joan Mendivil; Ryan Murphy; Marie de la Cruz; Ellen Janssen; Henrik Balle Boysen; Gagan Jain; Emel Aygören-Pürsün; Ishan Hirji; Giovanna Devercelli
Journal:  Orphanet J Rare Dis       Date:  2021-02-18       Impact factor: 4.123

Review 7.  Assessment and management of disease burden and quality of life in patients with hereditary angioedema: a consensus report.

Authors:  Konrad Bork; John T Anderson; Teresa Caballero; Timothy Craig; Douglas T Johnston; H Henry Li; Hilary J Longhurst; Cristine Radojicic; Marc A Riedl
Journal:  Allergy Asthma Clin Immunol       Date:  2021-04-19       Impact factor: 3.406

8.  Psychometric study of the SF-36v2 in hereditary angioedema due to C1 inhibitor deficiency (C1-INH-HAE).

Authors:  Paola Palao-Ocharan; Nieves Prior; Elia Pérez-Fernández; Magdalena Caminoa; Teresa Caballero
Journal:  Orphanet J Rare Dis       Date:  2022-03-02       Impact factor: 4.123

9.  Consider Hereditary Angioedema in the Differential Diagnosis for Unexplained Recurring Abdominal Pain.

Authors:  Kyle Staller; Anthony Lembo; Aleena Banerji; Jonathan A Bernstein; Eric D Shah; Marc A Riedl
Journal:  J Clin Gastroenterol       Date:  2022-08-15       Impact factor: 3.174

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.